Receipt of PARP Inhibitors in Patients With Metastatic Prostate Cancer Harboring BRCA1/2 Alterations

医学 前列腺癌 PARP抑制剂 肿瘤科 内科学 癌症 恩扎鲁胺 队列 奥拉帕尼 逻辑回归 回顾性队列研究 聚ADP核糖聚合酶 雄激素受体 聚合酶 生物 生物化学 基因
作者
Micah Ostrowski,Yeonjung Jo,Chadi Hage Chehade,Zeynep İrem Özay,Georges Gebrael,Nicolas Sayegh,Edwin Lin,Ayana Srivastava,Abigail Gordhamer,Richard Ji,Haoran Li,Vinay Mathew Thomas,Sumati Gupta,Irbaz Bin Riaz,Benjamin L. Maughan,Soumyajit Roy,Neeraj Agarwal,Umang Swami
出处
期刊:JAMA network open [American Medical Association]
卷期号:8 (10): e2534968-e2534968
标识
DOI:10.1001/jamanetworkopen.2025.34968
摘要

Importance Patients with metastatic castration–resistant prostate cancer (mCRPC) harboring BRCA1/2 alterations are eligible to receive poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors as single agents or in combination with an androgen receptor pathway inhibitor after these agents showed survival improvement in their landmark clinical trials. However, data are limited regarding the uptake of PARP inhibitors in these patients. Objective To investigate the use of PARP inhibitors in patients with mCRPC harboring BRCA1/2 alterations. Design, Setting, and Participants This retrospective cohort study used the deidentified Flatiron-Health electronic health record–derived database of US community and academic practices to extract patient-level data. The data cutoff date was May 31, 2024. Patients with mCRPC with evidence of harboring BRCA1/2 alterations and alive after August 15, 2020 (ie, 3 months after the approval of the first PARP inhibitor, rucaparib, in mCRPC) were included. Statistical analysis was performed from September 2024 to May 2025. Exposures Age, race and ethnicity, insurance status, and practice type at the time of mCRPC diagnosis. Main Outcomes and Measures The receipt of PARP inhibitors. Multivariable logistic regression was conducted to assess the association between the exposures and the main outcome. Results Of 24 105 patients with metastatic prostate cancer, 443 male patients (median [IQR] age, 72 [65-79] years) had mCRPC with BRCA1/2 alterations and were eligible and included in our analysis. Of these patients, 227 (51.2%) received a PARP inhibitor, whereas 216 (48.8%) did not. Compared with patients covered by a commercial health plan, those covered by Medicare were significantly more likely to receive a PARP inhibitor (odds ratio, 1.91; 95% CI, 1.02-3.66; P = .047). The odds of receiving a PARP inhibitor were not significantly higher in patients treated in community practice compared with those treated in academic centers (odds ratio, 1.64; 95% CI, 1.00-2.70; P = .05). Conclusions and Relevance This retrospective cohort study of patients with mCRPC and evidence of BRCA1/2 alterations found that approximately half of patients did not receive PARP inhibitors despite evidence of survival improvement in this population. These findings highlight the need to increase awareness of the survival data and access to life-prolonging therapies in patients with mCRPC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
ccc发布了新的文献求助10
1秒前
范志鹏完成签到,获得积分20
2秒前
KuoHu关注了科研通微信公众号
2秒前
波风水门完成签到,获得积分10
2秒前
3秒前
万能图书馆的应助被tayyy采纳,获得10
3秒前
范志鹏发布了新的文献求助10
4秒前
4秒前
苒苒发布了新的文献求助10
4秒前
面包恐龙发布了新的文献求助10
4秒前
molihuakai的应助被7Wen采纳,获得10
5秒前
ldz完成签到 ,获得积分20
5秒前
wobisheng完成签到,获得积分10
5秒前
6秒前
晚风与海盐完成签到 ,获得积分10
6秒前
波风水门发布了新的文献求助10
6秒前
Jason完成签到 ,获得积分10
6秒前
9秒前
11秒前
面包恐龙完成签到,获得积分10
11秒前
11秒前
RolfHoward完成签到,获得积分10
11秒前
11秒前
小赵爱漂亮完成签到 ,获得积分10
12秒前
羊_完成签到,获得积分10
12秒前
14秒前
傻子发布了新的文献求助20
15秒前
15秒前
15秒前
Twinkle发布了新的文献求助10
16秒前
SciGPT的应助被威武的皮卡丘采纳,获得10
16秒前
秋风的应助被Linkkk采纳,获得10
16秒前
17秒前
完美世界的应助被科研通管家采纳,获得10
17秒前
yang完成签到 ,获得积分10
17秒前
CarryLJR的应助被科研通管家采纳,获得10
17秒前
17秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189382
求助须知:如何正确求助?哪些是违规求助? 9576691
关于积分的说明 21849410
捐赠科研通 7787318
什么是DOI,文献DOI怎么找? 3435538
关于科研通互助平台的介绍 2559748
邀请新用户注册赠送积分活动 2482509